Sy-Shi Wang, Ph.D.

Janssen Pharmaceutical
Brisbane, California, United States

Disclosure(s): Janssen Research & Development LLC: Employee, Stocks/Bonds (Public Company)

Presentation(s):

• 319 - Single-Dose and Repeat Single-Dose Ascending Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza

  Friday, October 18, 2024
  12:30 PM - 12:35 PM US PT

• 573 - CD388, a Novel Drug-Fc Conjugate (DFC), Demonstrates Prophylactic Activity in an Influenza Human Challenge Model

  Saturday, October 19, 2024
  2:21 PM - 2:39 PM US PT